Physician profile
Derek Tai
NPI 1639874969
$1,920.67
in general payments reported to CMS, 2019-2025
11 companies · $782 in 2025
The $782 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $1,016 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $46.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.97 |
| Education | $46.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $288.14 | 2024 | Terlivaz |
| Abbvie INC. | $249.98 | 2025 | Venclexta, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $240.24 | 2024-2025 | Abecma, Reblozyl |
| Syndax Pharmaceuticals, INC. | $205.53 | 2025 | Revuforj |
| Incyte Corporation | $202.19 | 2024-2025 | Jakafi, Jakafi |
| Genzyme Corporation | $195.16 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2024 | Calquence |
| Glaxosmithkline, LLC. | $121.91 | 2025 | Ojjaara |
| Jazz Pharmaceuticals INC. | $121.82 | 2023 | Vyxeos |
| Sobi, INC | $114.00 | 2024 | |
| Lilly USA, LLC | $46.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Tai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.